Compounds > bosentan anhydrous
Page last updated: 2024-08-26

bosentan anhydrous and bortezomib

bosentan anhydrous has been researched along with bortezomib in 6 studies

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (16.67)29.6817
2010's5 (83.33)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bagnato, A; Bonalumi, A; Cassaro, A; Cassatella, MA; Giacomazzi, A; Gottardi, M; Mosna, F; Rigo, A; Rosanò, L; Russignan, A; Salvadori, U; Scupoli, MT; Spina, C; Tamassia, N; Tecchio, C; Tinelli, M; Vinante, F; Zamò, A; Zanatta, L1
Schäfer, J; Theile, D; Weiss, J1

Reviews

1 review(s) available for bosentan anhydrous and bortezomib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

5 other study(ies) available for bosentan anhydrous and bortezomib

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
    Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests

2013
Endothelin-1 receptor blockade as new possible therapeutic approach in multiple myeloma.
    British journal of haematology, 2017, Volume: 178, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Autocrine Communication; Bortezomib; Bosentan; Cell Proliferation; Cell Survival; DNA Methylation; DNA, Neoplasm; Drug Synergism; Endothelin A Receptor Antagonists; Endothelin-1; Female; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Molecular Targeted Therapy; Multiple Myeloma; Plasma Cells; Promoter Regions, Genetic; Receptor, Endothelin A; Sulfonamides; Tumor Cells, Cultured

2017
Bosentan enhances in vitro bortezomib's anti-proliferative potency against multiple myeloma by mechanisms going beyond endothelin receptor blockade.
    British journal of haematology, 2019, Volume: 184, Issue:6

    Topics: Bortezomib; Bosentan; Endothelin-1; Humans; Multiple Myeloma; Receptor, Endothelin A

2019